首页 > 最新文献

Kidney Diseases最新文献

英文 中文
Development and Validation of a Clinical Prediction Model for Stages of Acute Kidney Injury in Critically Ill Patients. 危重患者急性肾损伤分期临床预测模型的建立与验证。
IF 3.2 4区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-03-14 eCollection Date: 2025-01-01 DOI: 10.1159/000545150
Nam Nguyen-Hoang, Wenbo Zhang, Jacqueline Koeze, Harold Snieder, Eric Keus, Gerton Lunter

Introduction: Among critically ill patients, acute kidney injury (AKI) has a high incidence and leads to poor prognosis. As AKI is often only detected well after onset, early risk stratification is crucial. This study aimed to develop and internally validate the first clinical prediction model for different stages of AKI in critically ill adults.

Methods: We utilized data from the Simple Intensive Care Studies II (SICS-II), a prospective cohort study at the University Medical Center Groningen, the Netherlands. The prognostic outcome was the highest KDIGO-based stage of AKI within the first 7 days of ICU stay. Candidate predictors included fifty-nine readily available variables in critical care. Least absolute shrinkage and selection operator and proportional odds logistic regression were used for variable selection and model estimation, respectively. Receiver operating characteristic (ROC) curve, calibration plot, and decision curve analysis were applied to evaluate model performance and clinical usefulness.

Results: Of the SICS-II cohort, 976 patients were eligible for our analyses (median [interquartile range] age 64 [52-72] years, 38% female). Within 7 days after ICU admission, 29%, 23%, and 14% of patients progressed to their highest severity of AKI at stages 1, 2, and 3, respectively. We derived a 15-variable model for predicting this maximum ordinal outcome with an area under the ROC curve of 0.76 (95% CI, 0.74-0.78) in bootstrap validation. The model showed good calibration and improved net benefit in decision curve analysis over a range of clinically plausible thresholds.

Conclusion: Using readily available predictors in the ICU setting, we could develop a prediction model for different stages of AKI with good performance and promising clinical usefulness. Our findings serve as an initial step towards applying a valid and timely prediction model for AKI severity, possibly helping to limit morbidity and improve patient outcomes.

急性肾损伤(acute kidney injury, AKI)在危重症患者中发病率高,预后差。由于AKI通常在发病后才被发现,因此早期风险分层至关重要。本研究旨在开发并内部验证危重成人不同阶段AKI的首个临床预测模型。方法:我们使用来自简单重症监护研究II (SICS-II)的数据,这是荷兰格罗宁根大学医学中心的一项前瞻性队列研究。预后结果为ICU住院前7天内AKI的kdigo最高分期。候选预测因子包括重症监护中59个现成的变量。最小绝对收缩和选择算子和比例赔率逻辑回归分别用于变量选择和模型估计。采用受试者工作特征(ROC)曲线、校正图和决策曲线分析评价模型的性能和临床应用价值。结果:在SICS-II队列中,976例患者符合我们的分析(中位[四分位数范围]年龄64[52-72]岁,38%为女性)。在ICU入院后7天内,29%、23%和14%的患者分别在第1期、第2期和第3期进展到AKI的最高严重程度。我们推导了一个15变量模型来预测这个最大有序结果,在bootstrap验证中,ROC曲线下面积为0.76 (95% CI, 0.74-0.78)。该模型在临床上合理的阈值范围内显示出良好的校准和改进的决策曲线分析的净效益。结论:利用ICU环境中现成的预测因子,我们可以建立不同阶段AKI的预测模型,具有良好的性能和良好的临床应用前景。我们的研究结果为应用有效和及时的AKI严重程度预测模型迈出了第一步,可能有助于限制发病率和改善患者预后。
{"title":"Development and Validation of a Clinical Prediction Model for Stages of Acute Kidney Injury in Critically Ill Patients.","authors":"Nam Nguyen-Hoang, Wenbo Zhang, Jacqueline Koeze, Harold Snieder, Eric Keus, Gerton Lunter","doi":"10.1159/000545150","DOIUrl":"https://doi.org/10.1159/000545150","url":null,"abstract":"<p><strong>Introduction: </strong>Among critically ill patients, acute kidney injury (AKI) has a high incidence and leads to poor prognosis. As AKI is often only detected well after onset, early risk stratification is crucial. This study aimed to develop and internally validate the first clinical prediction model for different stages of AKI in critically ill adults.</p><p><strong>Methods: </strong>We utilized data from the Simple Intensive Care Studies II (SICS-II), a prospective cohort study at the University Medical Center Groningen, the Netherlands. The prognostic outcome was the highest KDIGO-based stage of AKI within the first 7 days of ICU stay. Candidate predictors included fifty-nine readily available variables in critical care. Least absolute shrinkage and selection operator and proportional odds logistic regression were used for variable selection and model estimation, respectively. Receiver operating characteristic (ROC) curve, calibration plot, and decision curve analysis were applied to evaluate model performance and clinical usefulness.</p><p><strong>Results: </strong>Of the SICS-II cohort, 976 patients were eligible for our analyses (median [interquartile range] age 64 [52-72] years, 38% female). Within 7 days after ICU admission, 29%, 23%, and 14% of patients progressed to their highest severity of AKI at stages 1, 2, and 3, respectively. We derived a 15-variable model for predicting this maximum ordinal outcome with an area under the ROC curve of 0.76 (95% CI, 0.74-0.78) in bootstrap validation. The model showed good calibration and improved net benefit in decision curve analysis over a range of clinically plausible thresholds.</p><p><strong>Conclusion: </strong>Using readily available predictors in the ICU setting, we could develop a prediction model for different stages of AKI with good performance and promising clinical usefulness. Our findings serve as an initial step towards applying a valid and timely prediction model for AKI severity, possibly helping to limit morbidity and improve patient outcomes.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"226-239"},"PeriodicalIF":3.2,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12040308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Manifestations and Prognosis of Chronic Kidney Disease after Hematopoietic Stem Cell Transplantation. 造血干细胞移植后慢性肾脏疾病的临床表现及预后。
IF 3.2 4区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-03-12 eCollection Date: 2025-01-01 DOI: 10.1159/000545198
Yu Zhang, Guisheng Ren, Wencui Chen, Jinzhou Guo, Xiaomei Wu, Weiwei Xu, Xianghua Huang

Introduction: Kidney disease is a common complication of hematopoietic stem cell transplantation (HSCT). However, there is limited research on the clinical pathology and prognosis of patients who develop chronic kidney disease (CKD) after HSCT.

Methods: A retrospective analysis was conducted on 50 patients diagnosed with CKD through kidney biopsy between September 2008 and May 2024. The patients were categorized based on their pathological presentations into groups with thrombotic microangiopathy (TMA) or membranous nephropathy (MN).

Results: The renal pathological results revealed that TMA was the most prevalent pathological type, accounting for 40% of cases, followed by MN at 32%, and mesangial proliferative glomerulonephritis at 16%, among others. Clinically, patients with TMA predominantly presented with renal insufficiency, whereas those with MN mainly exhibited nephrotic syndrome. Patients with MN showed favorable responses to treatment, achieving complete and partial response rates of 14.3% and 71.4%, respectively. Among the 50-patient cohort, 45 remained alive, corresponding to a 5-year overall survival rate of 87.8%. The 5-year renal survival rate was observed to be 78.8%, with 3 patients (6.98%) requiring kidney replacement therapy.

Conclusion: TMA and MN are the two most common pathological findings in patients with CKD following HSCT. Both conditions exhibit favorable responses to combined steroids and immunosuppressant therapy. Notably, patients with MN demonstrate a higher overall response rate and superior treatment outcomes compared to those with TMA.

肾脏疾病是造血干细胞移植(HSCT)的常见并发症。然而,对于HSCT后发生慢性肾脏疾病(CKD)患者的临床病理和预后研究有限。方法:回顾性分析2008年9月至2024年5月通过肾活检诊断为CKD的50例患者。患者根据其病理表现分为血栓性微血管病变(TMA)组和膜性肾病(MN)组。结果:肾脏病理结果显示,TMA是最常见的病理类型,占40%,其次是MN(32%),系膜增生性肾小球肾炎(16%)等。临床上,TMA患者主要表现为肾功能不全,而MN患者主要表现为肾病综合征。MN患者对治疗反应良好,完全缓解率为14.3%,部分缓解率为71.4%。在50例患者队列中,45例患者存活,5年总生存率为87.8%。5年肾脏存活率为78.8%,其中3例(6.98%)需要肾脏替代治疗。结论:TMA和MN是HSCT后CKD患者最常见的两种病理表现。这两种情况都表现出对类固醇和免疫抑制剂联合治疗的有利反应。值得注意的是,与TMA患者相比,MN患者表现出更高的总体缓解率和更好的治疗结果。
{"title":"Clinical Manifestations and Prognosis of Chronic Kidney Disease after Hematopoietic Stem Cell Transplantation.","authors":"Yu Zhang, Guisheng Ren, Wencui Chen, Jinzhou Guo, Xiaomei Wu, Weiwei Xu, Xianghua Huang","doi":"10.1159/000545198","DOIUrl":"https://doi.org/10.1159/000545198","url":null,"abstract":"<p><strong>Introduction: </strong>Kidney disease is a common complication of hematopoietic stem cell transplantation (HSCT). However, there is limited research on the clinical pathology and prognosis of patients who develop chronic kidney disease (CKD) after HSCT.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 50 patients diagnosed with CKD through kidney biopsy between September 2008 and May 2024. The patients were categorized based on their pathological presentations into groups with thrombotic microangiopathy (TMA) or membranous nephropathy (MN).</p><p><strong>Results: </strong>The renal pathological results revealed that TMA was the most prevalent pathological type, accounting for 40% of cases, followed by MN at 32%, and mesangial proliferative glomerulonephritis at 16%, among others. Clinically, patients with TMA predominantly presented with renal insufficiency, whereas those with MN mainly exhibited nephrotic syndrome. Patients with MN showed favorable responses to treatment, achieving complete and partial response rates of 14.3% and 71.4%, respectively. Among the 50-patient cohort, 45 remained alive, corresponding to a 5-year overall survival rate of 87.8%. The 5-year renal survival rate was observed to be 78.8%, with 3 patients (6.98%) requiring kidney replacement therapy.</p><p><strong>Conclusion: </strong>TMA and MN are the two most common pathological findings in patients with CKD following HSCT. Both conditions exhibit favorable responses to combined steroids and immunosuppressant therapy. Notably, patients with MN demonstrate a higher overall response rate and superior treatment outcomes compared to those with TMA.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"195-205"},"PeriodicalIF":3.2,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144017221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Precision Treatment of IgA Nephropathy Based on a New Framework: Angiorenal Protection, Immunity Inhibition, B-Cell/Plasma-Cell Modulation, and Complement Inhibition. 基于新框架的IgA肾病精准治疗:血管肾保护、免疫抑制、b细胞/浆细胞调节和补体抑制。
IF 3.2 4区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-03-07 eCollection Date: 2025-01-01 DOI: 10.1159/000544998
Cheng Xue, Shengqiang Yu, Wei Gou, Yelei Xu, Li Yang, Bing Dai
{"title":"Precision Treatment of IgA Nephropathy Based on a New Framework: Angiorenal Protection, Immunity Inhibition, B-Cell/Plasma-Cell Modulation, and Complement Inhibition.","authors":"Cheng Xue, Shengqiang Yu, Wei Gou, Yelei Xu, Li Yang, Bing Dai","doi":"10.1159/000544998","DOIUrl":"10.1159/000544998","url":null,"abstract":"","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"154-159"},"PeriodicalIF":3.2,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic Value of Blood Pressure Rhythmicity for Estimated Glomerular Filtration Rate in Male Hypertensive Patients Aged 55 and Older. 血压节律对 55 岁及以上男性高血压患者估计肾小球滤过率的预后价值。
IF 3.2 4区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-03-06 eCollection Date: 2025-01-01 DOI: 10.1159/000544992
Lulu Wang, Han Tian, Xinxin Xu, Xinyan Gu, Liu Li, Hui Zheng, Jie Xu, Chunsun Dai, Lei Jiang

Introduction: Blood pressure (BP) exhibits a circadian rhythm characterized by higher levels during wakefulness and lower levels during sleep; however, the functional and structural impact of the rhythms of BP remains uncertain.

Methods: Two hundred hypertensive males aged 55 and older without overt cardiovascular or cerebrovascular diseases were enrolled in this longitudinal study. Of these, 188 were included in the analyses (12 lacked valid BP records for part of the 24-h period). Rhythmic profiling of BP was performed using ARSER, and rhythmicity was considered significant at p < 0.05. Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology (CKD-EPI) formula. The primary outcome was the change in eGFR.

Results: The average age was 64.9 ± 7.2 years. For systolic BP (SBP), 38 of the subjects exhibited a 12-h rhythm and 43 subjects a 24-h rhythm; for diastolic BP (DBP), 38 exhibited a 12-h rhythm, and 36 exhibited a 24-h rhythm. During the 3-year follow-up period, 16 of the subjects died, and 36 were lost to follow-up. The mean eGFR at baseline and follow-up were, respectively, 86.6 ± 14.0 and 81.0 ± 17.1 mL min-1 1.73 m-2 (p = 0.001). The urinary albumin:creatinine ratio did not vary significantly among the groups (p = 0.059). Subjects with 12-h rhythmic SBP exhibited a smaller reduction in eGFR than those with arrhythmic SBP (p = 0.014). However, the changes in eGFR were similar among the groups displaying 12-h or 24-h rhythmic DBP or arrhythmic DBP. We defined a decline in eGFR as a reduction of >1/2 SD between baseline and follow-up. Adjusting for confounding factors (including age, smoking, alcohol consumption, diabetes mellitus, BMI, albumin levels, administration time of antihypertensive drugs, and duration of hypertension), the risk of a decline in eGFR was 70% lower in subjects with 12-h rhythmic SBP than in those with arrhythmic SBP (heart rate = 0.307 [0.108-0.874], p = 0.027).

Conclusion: SBP with a 12-h period is a protective predictor of the decline in eGFR in hypertensive males. It is, therefore, necessary to focus on the rhythmic profiling of BP.

血压(BP)表现出一种昼夜节律,其特点是清醒时血压较高,睡眠时血压较低;然而,BP节律的功能和结构影响仍不确定。方法:200名55岁及以上无明显心脑血管疾病的男性高血压患者参加了这项纵向研究。其中,188例纳入分析(12例缺乏部分24小时内的有效BP记录)。采用ARSER进行血压节律谱分析,节律性被认为是显著的p < 0.05。估算肾小球滤过率(eGFR)使用慢性肾脏疾病流行病学(CKD-EPI)公式计算。主要结局是eGFR的变化。结果:患者平均年龄64.9±7.2岁。收缩压(SBP)方面,38名受试者表现为12小时节律,43名受试者表现为24小时节律;舒张压(DBP), 38例为12 h节律,36例为24 h节律。3年随访期间,死亡16例,失访36例。基线和随访时的平均eGFR分别为86.6±14.0和81.0±17.1 mL min-1 1.73 m-2 (p = 0.001)。尿白蛋白:肌酐比值各组间差异无统计学意义(p = 0.059)。节律性收缩压12小时的受试者eGFR下降幅度小于节律性收缩压不规律者(p = 0.014)。然而,在12小时、24小时节律性舒张和非节律性舒张组中,eGFR的变化是相似的。我们将eGFR的下降定义为基线和随访之间减少了1/2个标准差。调整混杂因素(包括年龄、吸烟、饮酒、糖尿病、BMI、白蛋白水平、降压药物给药时间、高血压持续时间)后,12小时节律性收缩压组eGFR下降的风险比非节律性收缩压组低70%(心率= 0.307 [0.108-0.874],p = 0.027)。结论:12h周期收缩压是男性高血压患者eGFR下降的保护性预测因子。因此,有必要关注BP的节奏特征。
{"title":"Prognostic Value of Blood Pressure Rhythmicity for Estimated Glomerular Filtration Rate in Male Hypertensive Patients Aged 55 and Older.","authors":"Lulu Wang, Han Tian, Xinxin Xu, Xinyan Gu, Liu Li, Hui Zheng, Jie Xu, Chunsun Dai, Lei Jiang","doi":"10.1159/000544992","DOIUrl":"10.1159/000544992","url":null,"abstract":"<p><strong>Introduction: </strong>Blood pressure (BP) exhibits a circadian rhythm characterized by higher levels during wakefulness and lower levels during sleep; however, the functional and structural impact of the rhythms of BP remains uncertain.</p><p><strong>Methods: </strong>Two hundred hypertensive males aged 55 and older without overt cardiovascular or cerebrovascular diseases were enrolled in this longitudinal study. Of these, 188 were included in the analyses (12 lacked valid BP records for part of the 24-h period). Rhythmic profiling of BP was performed using ARSER, and rhythmicity was considered significant at <i>p</i> < 0.05. Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology (CKD-EPI) formula. The primary outcome was the change in eGFR.</p><p><strong>Results: </strong>The average age was 64.9 ± 7.2 years. For systolic BP (SBP), 38 of the subjects exhibited a 12-h rhythm and 43 subjects a 24-h rhythm; for diastolic BP (DBP), 38 exhibited a 12-h rhythm, and 36 exhibited a 24-h rhythm. During the 3-year follow-up period, 16 of the subjects died, and 36 were lost to follow-up. The mean eGFR at baseline and follow-up were, respectively, 86.6 ± 14.0 and 81.0 ± 17.1 mL min<sup>-1</sup> 1.73 m<sup>-2</sup> (<i>p</i> = 0.001). The urinary albumin:creatinine ratio did not vary significantly among the groups (<i>p</i> = 0.059). Subjects with 12-h rhythmic SBP exhibited a smaller reduction in eGFR than those with arrhythmic SBP (<i>p</i> = 0.014). However, the changes in eGFR were similar among the groups displaying 12-h or 24-h rhythmic DBP or arrhythmic DBP. We defined a decline in eGFR as a reduction of >1/2 SD between baseline and follow-up. Adjusting for confounding factors (including age, smoking, alcohol consumption, diabetes mellitus, BMI, albumin levels, administration time of antihypertensive drugs, and duration of hypertension), the risk of a decline in eGFR was 70% lower in subjects with 12-h rhythmic SBP than in those with arrhythmic SBP (heart rate = 0.307 [0.108-0.874], <i>p</i> = 0.027).</p><p><strong>Conclusion: </strong>SBP with a 12-h period is a protective predictor of the decline in eGFR in hypertensive males. It is, therefore, necessary to focus on the rhythmic profiling of BP.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"186-193"},"PeriodicalIF":3.2,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Uric Acid and Atherosclerosis in Patients with Chronic Kidney Disease: Recent Progress, Mechanisms, and Prospect. 慢性肾病患者的尿酸和动脉粥样硬化:最新进展、机理与展望》。
IF 3.2 4区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-03-03 eCollection Date: 2025-01-01 DOI: 10.1159/000543781
Yuchu Liu, Zeyu Li, Yuanwen Xu, Haiping Mao, Naya Huang

Background: Chronic kidney disease (CKD) is a prevalent global health concern, significantly linked to increased cardiovascular morbidity and mortality. Among various risk factors, uric acid (UA) has emerged as a potentially modifiable contributor to cardiovascular complications in CKD patients.

Summary: Elevated serum uric acid levels frequently occur in individuals with CKD and are associated with the development of atherosclerosis (AS). Uric acid has been demonstrated to exacerbate inflammatory processes, promote oxidative stress, and cause endothelial dysfunction, which are critical factors that drive the formation of atherosclerotic plaques. Furthermore, high uric acid levels can worsen renal function, establishing a detrimental cycle that amplifies cardiovascular risk.

Key messages: This review investigates the complex interconnection between UA and AS in patients with CKD, highlighting the underlying mechanisms and therapeutic considerations. A more profound comprehension of this relationship is essential for enhancing cardiovascular health and outcomes in this vulnerable population.

背景:慢性肾脏疾病(CKD)是一种普遍的全球健康问题,与心血管发病率和死亡率的增加显著相关。在各种危险因素中,尿酸(UA)已成为CKD患者心血管并发症的潜在可改变因素。总结:血清尿酸水平升高经常发生在CKD患者中,并与动脉粥样硬化(AS)的发展有关。尿酸已被证明会加剧炎症过程,促进氧化应激,并导致内皮功能障碍,这些都是驱动动脉粥样硬化斑块形成的关键因素。此外,高尿酸水平会使肾功能恶化,形成一个恶性循环,增加心血管风险。本综述探讨了CKD患者UA和AS之间的复杂联系,强调了潜在的机制和治疗注意事项。更深刻地理解这种关系对于加强这一弱势群体的心血管健康和预后至关重要。
{"title":"Uric Acid and Atherosclerosis in Patients with Chronic Kidney Disease: Recent Progress, Mechanisms, and Prospect.","authors":"Yuchu Liu, Zeyu Li, Yuanwen Xu, Haiping Mao, Naya Huang","doi":"10.1159/000543781","DOIUrl":"10.1159/000543781","url":null,"abstract":"<p><strong>Background: </strong>Chronic kidney disease (CKD) is a prevalent global health concern, significantly linked to increased cardiovascular morbidity and mortality. Among various risk factors, uric acid (UA) has emerged as a potentially modifiable contributor to cardiovascular complications in CKD patients.</p><p><strong>Summary: </strong>Elevated serum uric acid levels frequently occur in individuals with CKD and are associated with the development of atherosclerosis (AS). Uric acid has been demonstrated to exacerbate inflammatory processes, promote oxidative stress, and cause endothelial dysfunction, which are critical factors that drive the formation of atherosclerotic plaques. Furthermore, high uric acid levels can worsen renal function, establishing a detrimental cycle that amplifies cardiovascular risk.</p><p><strong>Key messages: </strong>This review investigates the complex interconnection between UA and AS in patients with CKD, highlighting the underlying mechanisms and therapeutic considerations. A more profound comprehension of this relationship is essential for enhancing cardiovascular health and outcomes in this vulnerable population.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"112-127"},"PeriodicalIF":3.2,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetically Predicted Causal Relationship between Gut Microbiota and Various Kidney Diseases. 肠道微生物群与各种肾脏疾病的遗传预测因果关系。
IF 3.2 4区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-02-27 eCollection Date: 2025-01-01 DOI: 10.1159/000544915
Zi-Jin Chen, Rui Wang, Meng-Ying Yao, Jing-Hong Zhao, Bo Liang

Introduction: Although recent research suggests that alterations in gut microbiota play a critical role in the pathophysiology of kidney diseases, the causal relationship between specific intestinal flora and the risk of kidney diseases remains unclear. Here, we investigated the causal relationship between gut microbiota and different kidney diseases through mendelian randomization analysis.

Methods: Gut microbiota and three types of kidney diseases, including diabetic nephropathy, IgA nephropathy, and membranous nephropathy, were identified from large-scale genome-wide association studies summary data. Inverse variance weighted method was employed to estimate causal relationships. Cochran's Q test was utilized to uncover any heterogeneity. The mendelian randomization-Egger intercept test was employed to detect horizontal pleiotropy, and the leave-one-out method was used for testing the stability. In addition, the reverse, multivariable, and two-step mendelian randomization analysis was conducted to assess the causation possibilities. Furthermore, the associations between three types of kidney diseases and immune infiltration were determined.

Results: We identified 1,531 single-nucleotide polymorphisms. There were 6 positive and 9 negative causal effects between gut microbiota and three types of kidney diseases. Specifically, Dialister was a protective factor for diabetic nephropathy while Lachnospiraceae UCG-008 was a risk factor. Clostridium innocuum was a protective factor for IgA nephropathy, while Christensenellaceae R.7, Clostridium sensu stricto1, Lachnospiraceae UCG-004, Lachnospiraceae UCG-010, Oscillospira, Ruminococcaceae UCG-010, and Terrisporobacter were risk factors for IgA nephropathy. Butyricicoccus, Catenibacterium, Flavonifractor, and Lachnospira were associated with an increased risk of membranous nephropathy, while Ruminococcaceae UCG-011 was associated with a decreased risk of membranous nephropathy. Sensitivity analysis indicated the results were robust. No significant pleiotropy or heterogeneity was identified. Notably, the reverse mendelian randomization analysis did not reveal any causal relationship. After adjusting for environmental confounders, including CO, PM 2.5, PM 10, and exposure to tobacco smoke at home, these causal relationships still exist. Additionally, immune infiltration analysis indicated unique immune cell distribution in each type of kidney disease, which are largely consistent with later two-step approach, emphasizing the significance of immunological processes in the diseases.

Conclusion: This study uncovered the causal relationship between gut microbiota and three types of kidney diseases. This discovery provides fresh perspectives on how microbes contribute to kidney diseases, paving the way for more i

虽然最近的研究表明,肠道菌群的改变在肾脏疾病的病理生理中起着关键作用,但特定肠道菌群与肾脏疾病风险之间的因果关系尚不清楚。在这里,我们通过孟德尔随机分析研究了肠道微生物群与不同肾脏疾病之间的因果关系。方法:从大规模全基因组关联研究汇总数据中鉴定肠道微生物群和三种类型的肾脏疾病,包括糖尿病肾病、IgA肾病和膜性肾病。采用方差反加权法估计因果关系。科克伦Q测试被用来发现任何异质性。水平多效性检测采用孟德尔随机-艾格截距检验,稳定性检测采用留一法。此外,还进行了反向、多变量和两步孟德尔随机化分析来评估因果关系的可能性。此外,确定了三种肾脏疾病与免疫浸润之间的关系。结果:共鉴定出1531个单核苷酸多态性。肠道菌群与3种肾脏疾病之间存在6个正相关因果关系,9个负相关因果关系。具体来说,Dialister是糖尿病肾病的保护因素,而Lachnospiraceae UCG-008是危险因素。无害梭菌是IgA肾病的保护因子,而Christensenellaceae R.7、敏感梭菌1、毛螺科UCG-004、毛螺科UCG-010、Oscillospira、Ruminococcaceae UCG-010和Terrisporobacter是IgA肾病的危险因子。丁酸球菌、链状杆菌、黄酮因子和毛螺旋体与膜性肾病的风险增加相关,而瘤胃球菌科UCG-011与膜性肾病的风险降低相关。敏感性分析表明结果是稳健的。未发现明显的多效性或异质性。值得注意的是,反向孟德尔随机化分析没有揭示任何因果关系。在调整了环境混杂因素,包括一氧化碳、pm2.5、pm10和暴露于家中烟草烟雾后,这些因果关系仍然存在。此外,免疫浸润分析表明,每种肾脏疾病的免疫细胞分布都是独特的,这与后来的两步方法基本一致,强调了免疫过程在疾病中的重要性。结论:本研究揭示了肠道微生物群与三种肾脏疾病之间的因果关系。这一发现为微生物如何促进肾脏疾病提供了新的视角,为更深入的临床研究铺平了道路。
{"title":"Genetically Predicted Causal Relationship between Gut Microbiota and Various Kidney Diseases.","authors":"Zi-Jin Chen, Rui Wang, Meng-Ying Yao, Jing-Hong Zhao, Bo Liang","doi":"10.1159/000544915","DOIUrl":"10.1159/000544915","url":null,"abstract":"<p><strong>Introduction: </strong>Although recent research suggests that alterations in gut microbiota play a critical role in the pathophysiology of kidney diseases, the causal relationship between specific intestinal flora and the risk of kidney diseases remains unclear. Here, we investigated the causal relationship between gut microbiota and different kidney diseases through mendelian randomization analysis.</p><p><strong>Methods: </strong>Gut microbiota and three types of kidney diseases, including diabetic nephropathy, IgA nephropathy, and membranous nephropathy, were identified from large-scale genome-wide association studies summary data. Inverse variance weighted method was employed to estimate causal relationships. Cochran's <i>Q</i> test was utilized to uncover any heterogeneity. The mendelian randomization-Egger intercept test was employed to detect horizontal pleiotropy, and the leave-one-out method was used for testing the stability. In addition, the reverse, multivariable, and two-step mendelian randomization analysis was conducted to assess the causation possibilities. Furthermore, the associations between three types of kidney diseases and immune infiltration were determined.</p><p><strong>Results: </strong>We identified 1,531 single-nucleotide polymorphisms. There were 6 positive and 9 negative causal effects between gut microbiota and three types of kidney diseases. Specifically, <i>Dialister</i> was a protective factor for diabetic nephropathy while <i>Lachnospiraceae UCG-008</i> was a risk factor. <i>Clostridium innocuum</i> was a protective factor for IgA nephropathy, while <i>Christensenellaceae R.7</i>, <i>Clostridium sensu stricto</i>1, <i>Lachnospiraceae UCG-004</i>, <i>Lachnospiraceae UCG-010</i>, <i>Oscillospira</i>, <i>Ruminococcaceae UCG-010</i>, and <i>Terrisporobacter</i> were risk factors for IgA nephropathy. <i>Butyricicoccus</i>, <i>Catenibacterium</i>, <i>Flavonifractor</i>, and <i>Lachnospira</i> were associated with an increased risk of membranous nephropathy, while <i>Ruminococcaceae UCG-011</i> was associated with a decreased risk of membranous nephropathy. Sensitivity analysis indicated the results were robust. No significant pleiotropy or heterogeneity was identified. Notably, the reverse mendelian randomization analysis did not reveal any causal relationship. After adjusting for environmental confounders, including CO, PM 2.5, PM 10, and exposure to tobacco smoke at home, these causal relationships still exist. Additionally, immune infiltration analysis indicated unique immune cell distribution in each type of kidney disease, which are largely consistent with later two-step approach, emphasizing the significance of immunological processes in the diseases.</p><p><strong>Conclusion: </strong>This study uncovered the causal relationship between gut microbiota and three types of kidney diseases. This discovery provides fresh perspectives on how microbes contribute to kidney diseases, paving the way for more i","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"170-185"},"PeriodicalIF":3.2,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Novel Approach to Repositioning Peritoneal Dialysis Catheters. 一种重新定位腹膜透析导管的新方法。
IF 3.2 4区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-02-25 eCollection Date: 2025-01-01 DOI: 10.1159/000543824
Xiuling Chen, Nan Wang, Yurong Zou, Jin Chen, Hui Gao, Guisen Li, Junru Wang

Introduction: Peritoneal dialysis (PD) is a crucial kidney replacement therapy for patients with end-stage kidney disease. Despite its advantages over hemodialysis (HD), long-term success can be hindered by catheter dysfunction, which often necessitates revision. Currently, surgical treatment methods for PD catheter malfunction include fluoroscopy-guided procedures and laparoscopic or open surgery to salvage or replace the catheter. Here, we introduce the first novel, minimally invasive surgery for repositioning PD catheters.

Methods: From November 2021 to May 2024, 8 patients with PD catheter dysfunction underwent this innovative procedure at the Department of Nephrology, Sichuan Provincial People's Hospital. Surgical Procedure: On the side of the original abdominal incision, blunt separation was used to find the PD catheter tunnel segment. The anterior rectus abdominal muscle sheath was incised, followed by separation of the deep polyester sleeve. The original catheter was exposed in the abdominal port or purse-string suture, and the intra-abdominal segment of the dialysis catheter was pulled out. Blunt cleaning around the periphery was performed to ensure that the PD catheter was smooth, and a rigid guidewire was placed through the intra-abdominal segment of the proximal end of the catheter of the first lateral hole. The intra-abdominal segment of the PD catheter was placed into the pelvis via the original catheter in the abdominal port. Clinical data were retrospectively collected, and patients were followed up for safety and efficacy assessment.

Results: In a study involving 8 patients, no significant complications were observed, with an immediate imaging success rate of 100% and a clinical PD catheter reset success rate of 75%. The catheter remained patent until the end of the study, with a mean follow-up time of 17.25 ± 9.25 months.

Conclusion: This new method for resetting dysfunctional PD catheters demonstrates technical feasibility, simplicity, cost-effectiveness, and safety. It has the potential to emerge as an alternative, particularly suitable for resource-limited settings.

腹膜透析(PD)是终末期肾病患者重要的肾脏替代疗法。尽管它比血液透析(HD)有优势,但长期的成功可能会受到导管功能障碍的阻碍,这通常需要翻修。目前,PD导管故障的手术治疗方法包括透视引导下的手术和腹腔镜或开放手术来挽救或更换导管。在这里,我们介绍第一种新颖的微创手术来重新定位PD导管。方法:2021年11月至2024年5月,8例PD导管功能障碍患者在四川省人民医院肾内科接受了这一创新手术。手术方法:在原腹部切口一侧钝性分离寻找PD导管隧道段。切开腹前直肌鞘,然后分离深层聚酯套管。将原导管暴露于腹口或荷包缝合处,拔出腹内段透析导管。钝性清理周围周围,确保PD导管光滑,并在第一个外侧孔导管近端腹内段置入刚性导丝。腹内段PD导管经原腹口导管置入骨盆。回顾性收集临床资料,并随访患者进行安全性和有效性评估。结果:本研究共8例患者,未观察到明显并发症,即刻成像成功率100%,临床PD导管复位成功率75%。导管通畅至研究结束,平均随访时间17.25±9.25个月。结论:这种复位功能障碍PD导管的新方法具有技术可行性、简单性、成本效益和安全性。它有可能成为一种替代方法,特别适合于资源有限的环境。
{"title":"A Novel Approach to Repositioning Peritoneal Dialysis Catheters.","authors":"Xiuling Chen, Nan Wang, Yurong Zou, Jin Chen, Hui Gao, Guisen Li, Junru Wang","doi":"10.1159/000543824","DOIUrl":"10.1159/000543824","url":null,"abstract":"<p><strong>Introduction: </strong>Peritoneal dialysis (PD) is a crucial kidney replacement therapy for patients with end-stage kidney disease. Despite its advantages over hemodialysis (HD), long-term success can be hindered by catheter dysfunction, which often necessitates revision. Currently, surgical treatment methods for PD catheter malfunction include fluoroscopy-guided procedures and laparoscopic or open surgery to salvage or replace the catheter. Here, we introduce the first novel, minimally invasive surgery for repositioning PD catheters.</p><p><strong>Methods: </strong>From November 2021 to May 2024, 8 patients with PD catheter dysfunction underwent this innovative procedure at the Department of Nephrology, Sichuan Provincial People's Hospital. Surgical Procedure: On the side of the original abdominal incision, blunt separation was used to find the PD catheter tunnel segment. The anterior rectus abdominal muscle sheath was incised, followed by separation of the deep polyester sleeve. The original catheter was exposed in the abdominal port or purse-string suture, and the intra-abdominal segment of the dialysis catheter was pulled out. Blunt cleaning around the periphery was performed to ensure that the PD catheter was smooth, and a rigid guidewire was placed through the intra-abdominal segment of the proximal end of the catheter of the first lateral hole. The intra-abdominal segment of the PD catheter was placed into the pelvis via the original catheter in the abdominal port. Clinical data were retrospectively collected, and patients were followed up for safety and efficacy assessment.</p><p><strong>Results: </strong>In a study involving 8 patients, no significant complications were observed, with an immediate imaging success rate of 100% and a clinical PD catheter reset success rate of 75%. The catheter remained patent until the end of the study, with a mean follow-up time of 17.25 ± 9.25 months.</p><p><strong>Conclusion: </strong>This new method for resetting dysfunctional PD catheters demonstrates technical feasibility, simplicity, cost-effectiveness, and safety. It has the potential to emerge as an alternative, particularly suitable for resource-limited settings.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"104-111"},"PeriodicalIF":3.2,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11925479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Prognostic Index for Deceased Donor Kidneys and Criteria for Identifying Suitable Candidates for Kidney Transplantation from Expanded Criteria Donors with Prolonged Waiting Times. 死亡捐献者肾脏的预后指数以及从等待时间较长的扩大标准捐献者中确定肾移植合适候选者的标准。
IF 3.2 4区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-02-20 eCollection Date: 2025-01-01 DOI: 10.1159/000544792
Tai Yeon Koo, Joongyub Lee, Omi Na, Yonggu Lee, Jong Cheol Jeong, Jaeseok Yang

Introduction: The kidney donor profile index (KDPI) is a valuable prognostic tool in deceased donor kidney transplantation (DDKT), while its optimization for each country using local data is essential. It remains unclear which patients derive survival benefits from expanded criteria donor (ECD) DDKT compared to waitlist or standard criteria donor (SCD) DDKT, particularly in the context of long waiting times. This study aimed to develop a prognostic index for donor kidneys and propose criteria to identify suitable candidates for ECD DDKT in Korea.

Methods: Two prediction models were developed using data from two cohorts based on national databases (the Korean Network for Organ Sharing and the National Health Insurance Data Sharing Service): cohort for the prediction of graft prognosis (n = 6,272) and cohort for the prediction of suitable candidates for ECD DDKT (n = 30,183).

Results: The Korean KDPI (K-KDPI) comprises five donor factors (age, height, diabetes mellitus, serum creatinine levels, and hepatitis C virus), associated with graft failure. The discriminatory ability of the K-KDPI for graft outcomes surpassed that of the US KDPI and dichotomous ECD criteria. ECD kidneys (K-KDPI ≥70%) showed worse allograft survival compared to SCD kidneys (K-KDPI <70%). Candidates aged ≥40 years, with negative panel reactive antibody, and without diabetes mellitus had a significantly lower mortality risk with ECD DDKT than with waitlist-or-SCD DDKT, making them suitable for ECD DDKT.

Conclusion: The K-KDPI and criteria for identifying suitable ECD recipients are expected to improve the quality assessment and efficient utilization of ECD kidneys in Korea with long waiting times.

肾供者概况指数(KDPI)是一种有价值的预测已故供者肾移植(DDKT)的工具,而利用当地数据对每个国家进行优化是至关重要的。与等待名单或标准标准供体(SCD) DDKT相比,目前尚不清楚哪些患者从扩展标准供体(ECD) DDKT中获得生存益处,特别是在等待时间较长的情况下。本研究旨在制定供体肾脏的预后指数,并提出标准,以确定韩国ECD DDKT的合适候选人。方法:使用基于国家数据库(韩国器官共享网络和国民健康保险数据共享服务)的两个队列的数据建立了两个预测模型:预测移植物预后的队列(n = 6272)和预测适合ECD DDKT候选人的队列(n = 30,183)。结果:韩国KDPI (K-KDPI)包括与移植失败相关的5个供体因素(年龄、身高、糖尿病、血清肌酐水平和丙型肝炎病毒)。K-KDPI对移植结果的区分能力超过了美国KDPI和二分ECD标准。结论:K-KDPI和确定合适ECD受体的标准有望改善韩国等待时间较长的ECD肾脏的质量评估和有效利用。
{"title":"A Prognostic Index for Deceased Donor Kidneys and Criteria for Identifying Suitable Candidates for Kidney Transplantation from Expanded Criteria Donors with Prolonged Waiting Times.","authors":"Tai Yeon Koo, Joongyub Lee, Omi Na, Yonggu Lee, Jong Cheol Jeong, Jaeseok Yang","doi":"10.1159/000544792","DOIUrl":"10.1159/000544792","url":null,"abstract":"<p><strong>Introduction: </strong>The kidney donor profile index (KDPI) is a valuable prognostic tool in deceased donor kidney transplantation (DDKT), while its optimization for each country using local data is essential. It remains unclear which patients derive survival benefits from expanded criteria donor (ECD) DDKT compared to waitlist or standard criteria donor (SCD) DDKT, particularly in the context of long waiting times. This study aimed to develop a prognostic index for donor kidneys and propose criteria to identify suitable candidates for ECD DDKT in Korea.</p><p><strong>Methods: </strong>Two prediction models were developed using data from two cohorts based on national databases (the Korean Network for Organ Sharing and the National Health Insurance Data Sharing Service): cohort for the prediction of graft prognosis (<i>n</i> = 6,272) and cohort for the prediction of suitable candidates for ECD DDKT (<i>n</i> = 30,183).</p><p><strong>Results: </strong>The Korean KDPI (K-KDPI) comprises five donor factors (age, height, diabetes mellitus, serum creatinine levels, and hepatitis C virus), associated with graft failure. The discriminatory ability of the K-KDPI for graft outcomes surpassed that of the US KDPI and dichotomous ECD criteria. ECD kidneys (K-KDPI ≥70%) showed worse allograft survival compared to SCD kidneys (K-KDPI <70%). Candidates aged ≥40 years, with negative panel reactive antibody, and without diabetes mellitus had a significantly lower mortality risk with ECD DDKT than with waitlist-or-SCD DDKT, making them suitable for ECD DDKT.</p><p><strong>Conclusion: </strong>The K-KDPI and criteria for identifying suitable ECD recipients are expected to improve the quality assessment and efficient utilization of ECD kidneys in Korea with long waiting times.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"143-153"},"PeriodicalIF":3.2,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11952819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Cohort Study of the Long-Term Influences of SARS-CoV-2 on Kidney Allograft Outcomes in Chinese Recipients: 1-Year Follow-Up Experience. SARS-CoV-2对中国肾移植受者移植结果长期影响的队列研究:1年随访经验
IF 3.2 4区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-02-12 eCollection Date: 2025-01-01 DOI: 10.1159/000543935
Yisheng Ji, Shuang Fei, Hongsheng Ji, Fan OuYang, Runmin Ding, Li Sun, Hao Chen, Xiaobing Ju, Jun Tao, Zhijian Han, Mulong Du, Zijie Wang, Ruoyun Tan, Min Gu

Introduction: The aim of the study was to investigate the long-term effects of the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection and novel coronavirus disease (COVID-19) on prognosis of kidney transplant recipients.

Methods: A 1-year retrospective study was carried out among 362 domestic kidney transplant recipients who were divided into observational (COVID-19) and control groups. Stratification analysis was then carried out to investigate whether repeated infections and infection severity could influence graft prognosis. Kaplan-Meier curves assessed 1-year graft survival, while one-way analysis of variance (ANOVA) compared graft function and laboratory parameters. Generalized estimating equations and repeated-measures ANOVA confirmed the magnitude of the impact of COVID-19 on kidney grafts. Generalized logistic regression and Cox regression established a model for analyzing COVID-19 risk factors. Meta-analysis and subgroup analysis were performed for validation.

Results: Exposure of COVID-19 had a significant effect on graft function within 1 year (p < 0.001), and this kind of effect was mostly brought by severer infections in the stratification analysis regarding graft survival rate (p < 0.001), estimated glomerular filtration rate (eGFR) level (p < 0.001), and 1-year eGFR slope (p = 0.014). Diagnostic model showed tacrolimus patients are less likely to get severe COVID-19 than cyclosporine (p = 0.004). Hyperglycemia (p = 0.004) and low hemoglobin (p = 0.023) are adverse factors for severe pneumonia. Hemoptysis, hypo-lymphopenia, high procalcitonin and ferritin are linked to poor allograft outcomes with SARS-CoV-2 infection.

Conclusions: COVID-19 severity is linked to poor kidney allograft prognosis. Hyperglycemia, low hemoglobin, and drug protocols including cyclosporine rather than tacrolimus are correlated with COVID-19 pneumonia. Hemoptysis, low lymphocytes, high procalcitonin or ferritin were concerned with kidney allograft prognosis post-COVID-19.

前言:本研究旨在探讨新型严重急性呼吸综合征冠状病毒(SARS-CoV-2)感染和新型冠状病毒病(COVID-19)对肾移植受者预后的长期影响。方法:对362例国内肾移植受者进行为期1年的回顾性研究,将其分为观察组(COVID-19)和对照组。分层分析反复感染及感染严重程度对移植物预后的影响。Kaplan-Meier曲线评估1年移植物存活率,而单因素方差分析(ANOVA)比较移植物功能和实验室参数。广义估计方程和重复测量方差分析证实了COVID-19对肾移植的影响程度。广义logistic回归和Cox回归建立了COVID-19危险因素分析模型。进行meta分析和亚组分析进行验证。结果:COVID-19暴露对1年内移植物功能有显著影响(p < 0.001),且在移植物存活率(p < 0.001)、估计肾小球滤过率(eGFR)水平(p < 0.001)和1年eGFR斜率(p = 0.014)的分层分析中,这种影响主要是由严重感染带来的。诊断模型显示,他克莫司患者发生严重COVID-19的可能性低于环孢素患者(p = 0.004)。高血糖(p = 0.004)和低血红蛋白(p = 0.023)是重症肺炎的不利因素。咯血、淋巴细胞减少症、高降钙素原和高铁蛋白与SARS-CoV-2感染的同种异体移植物预后不良有关。结论:COVID-19严重程度与肾移植预后不良有关。高血糖、低血红蛋白和包括环孢素而非他克莫司在内的药物方案与COVID-19肺炎相关。咯血、低淋巴细胞、高降钙素原或高铁蛋白与covid -19术后肾移植预后有关。
{"title":"A Cohort Study of the Long-Term Influences of SARS-CoV-2 on Kidney Allograft Outcomes in Chinese Recipients: 1-Year Follow-Up Experience.","authors":"Yisheng Ji, Shuang Fei, Hongsheng Ji, Fan OuYang, Runmin Ding, Li Sun, Hao Chen, Xiaobing Ju, Jun Tao, Zhijian Han, Mulong Du, Zijie Wang, Ruoyun Tan, Min Gu","doi":"10.1159/000543935","DOIUrl":"10.1159/000543935","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of the study was to investigate the long-term effects of the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection and novel coronavirus disease (COVID-19) on prognosis of kidney transplant recipients.</p><p><strong>Methods: </strong>A 1-year retrospective study was carried out among 362 domestic kidney transplant recipients who were divided into observational (COVID-19) and control groups. Stratification analysis was then carried out to investigate whether repeated infections and infection severity could influence graft prognosis. Kaplan-Meier curves assessed 1-year graft survival, while one-way analysis of variance (ANOVA) compared graft function and laboratory parameters. Generalized estimating equations and repeated-measures ANOVA confirmed the magnitude of the impact of COVID-19 on kidney grafts. Generalized logistic regression and Cox regression established a model for analyzing COVID-19 risk factors. Meta-analysis and subgroup analysis were performed for validation.</p><p><strong>Results: </strong>Exposure of COVID-19 had a significant effect on graft function within 1 year (<i>p</i> < 0.001), and this kind of effect was mostly brought by severer infections in the stratification analysis regarding graft survival rate (<i>p</i> < 0.001), estimated glomerular filtration rate (eGFR) level (<i>p</i> < 0.001), and 1-year eGFR slope (<i>p</i> = 0.014). Diagnostic model showed tacrolimus patients are less likely to get severe COVID-19 than cyclosporine (<i>p</i> = 0.004). Hyperglycemia (<i>p</i> = 0.004) and low hemoglobin (<i>p</i> = 0.023) are adverse factors for severe pneumonia. Hemoptysis, hypo-lymphopenia, high procalcitonin and ferritin are linked to poor allograft outcomes with SARS-CoV-2 infection.</p><p><strong>Conclusions: </strong>COVID-19 severity is linked to poor kidney allograft prognosis. Hyperglycemia, low hemoglobin, and drug protocols including cyclosporine rather than tacrolimus are correlated with COVID-19 pneumonia. Hemoptysis, low lymphocytes, high procalcitonin or ferritin were concerned with kidney allograft prognosis post-COVID-19.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"128-142"},"PeriodicalIF":3.2,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11936455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143710425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of Fatty Acid-Binding Protein 4 as a Potential Biomarker and Therapeutic Target for Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. 脂肪酸结合蛋白4作为抗中性粒细胞细胞质抗体相关肾小球肾炎的潜在生物标志物和治疗靶点的鉴定。
IF 3.2 4区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-02-05 eCollection Date: 2025-01-01 DOI: 10.1159/000543940
Lu Cheng, Qian Ren, Jing Liu, Mei-Lian Yu, Rong-Shuang Huang, Fan Guo, Liang Ma, Shen-Ju Gou, Ping Fu

Introduction: Fatty acid-binding protein 4 (FABP4) is a novel adipokine that is critically involved in many inflammatory and immune diseases. However, the role of FABP4 in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (ANCA-GN) remains unclear. The current study aimed to investigate the role of FABP4 in patients with ANCA-GN.

Methods: Plasma and urine samples from 37 patients with active ANCA-GN and kidney biopsy specimens from another group of 56 patients with ANCA-GN were collected. The plasma and urinary levels of FABP4 were measured by enzyme-linked immunosorbent assay and the kidney FABP4 expression was determined by immunohistochemistry and immunofluorescence staining. Associations between FABP4 levels with clinical and pathologic parameters were analyzed. To further elucidate the role of FABP4 in ANCA-GN, a novel FABP4 inhibitor, BMS309403, was employed in a recognized rat model of experimental autoimmune vasculitis (EAV).

Results: Plasma and urinary levels of FABP4 in active ANCA-GN patients were significantly higher than those in normal controls {52.8 ± 23.6 ng/mL vs. 16.9 ± 8.8 ng/mL, p < 0.01; median 126.6 (interquartile range [IQR] 28.4-311.2) ng/g Cr vs. median 0.0 (IQR 0.0-0.0) ng/g Cr, p < 0.01, respectively}. Immunohistochemical analysis revealed higher glomerular and tubular expression of FABP4 in the kidneys of ANCA-GN patients than those in normal controls (0.015 ± 0.012 vs. 0.004 ± 0.003, p < 0.001; 0.053 ± 0.026 vs. 0.011 ± 0.010, p < 0.001, respectively). Moreover, for ANCA-GN patients, urinary FABP4 levels were significantly higher in active ANCA than those in remission (184.3 ± 187.0 ng/g Cr vs. 9.4 ± 23.9 ng/g Cr, p < 0.01). Correlation analysis showed that urinary levels of FABP4 correlated with serum creatinine (r = 0.596, p < 0.0001), urinary albumin/Cr (r = 0.523, p = 0.001), blood neutrophil ratio (r = 0.386, p = 0.018), PT (r = 0.583, p = 0.001), APTT (r = 0.364, p = 0.034), hemoglobin level (r = -0.398, p = 0.015), estimated glomerular filtration rate (r = -0.680, p < 0.0001), crescent proportion (r = 0.661, p = 0.032), and all-cause death of ANCA-GN patients (HR 2.93, 95% CI [1.05-8.19]). Furthermore, FABP4 inhibition by BMS309403 ameliorated renal injury in a rat mole of ANCA-GN.

Conclusions: Urinary FABP4 levels might reflect the disease activity and renal involvement of ANCA-associated vasculitis, and FABP4 might act as a promising therapeutic target against ANCA-GN.

脂肪酸结合蛋白4 (Fatty acid binding protein 4, FABP4)是一种新型脂肪因子,在许多炎症和免疫疾病中起重要作用。然而,FABP4在抗中性粒细胞胞浆抗体(ANCA)相关性肾小球肾炎(ANCA- gn)中的作用尚不清楚。本研究旨在探讨FABP4在ANCA-GN患者中的作用。方法:收集37例活动性ANCA-GN患者的血浆和尿液标本,另一组56例ANCA-GN患者的肾脏活检标本。采用酶联免疫吸附法检测血浆和尿液中FABP4的水平,采用免疫组织化学和免疫荧光染色法检测肾脏中FABP4的表达。分析FABP4水平与临床和病理参数的关系。为了进一步阐明FABP4在ANCA-GN中的作用,我们将一种新的FABP4抑制剂BMS309403应用于公认的实验性自身免疫性血管炎(EAV)大鼠模型。结果:活动性ANCA-GN患者血浆和尿中FABP4水平显著高于正常对照组(52.8±23.6 ng/mL vs. 16.9±8.8 ng/mL, p < 0.01);中位数126.6(四分位数间距[IQR] 28.4-311.2) ng/g Cr vs中位数0.0 (IQR为0.0-0.0)ng/g Cr, p均< 0.01}。免疫组化分析显示,ANCA-GN患者肾小球和肾小管FABP4的表达高于正常对照组(0.015±0.012 vs. 0.004±0.003,p < 0.001;0.053±0.026 vs. 0.011±0.010,p < 0.001)。此外,对于ANCA- gn患者,活动性ANCA患者尿FABP4水平显著高于缓解性ANCA患者(184.3±187.0 ng/g Cr vs. 9.4±23.9 ng/g Cr, p < 0.01)。相关分析表明,尿与血清肌酐水平的FABP4相关(r = 0.596, p < 0.0001),尿白蛋白/ Cr (r = 0.523, p = 0.001),血中性粒细胞比值(r = 0.386, p = 0.018), PT (r = 0.583, p = 0.001), APTT (r = 0.364, p = 0.034),血红蛋白水平(r = -0.398, p = 0.015),肾小球滤过率(r = -0.680, p < 0.0001),新月比例(r = 0.661, p = 0.032),和全因死亡ANCA-GN患者(HR 2.93, 95% CI[1.05 - -8.19])。此外,BMS309403抑制FABP4可改善ANCA-GN大鼠的肾损伤。结论:尿液FABP4水平可能反映anca相关性血管炎的疾病活动性和肾脏受累情况,FABP4可能作为一种有希望的治疗ANCA-GN的靶点。
{"title":"Identification of Fatty Acid-Binding Protein 4 as a Potential Biomarker and Therapeutic Target for Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis.","authors":"Lu Cheng, Qian Ren, Jing Liu, Mei-Lian Yu, Rong-Shuang Huang, Fan Guo, Liang Ma, Shen-Ju Gou, Ping Fu","doi":"10.1159/000543940","DOIUrl":"10.1159/000543940","url":null,"abstract":"<p><strong>Introduction: </strong>Fatty acid-binding protein 4 (FABP4) is a novel adipokine that is critically involved in many inflammatory and immune diseases. However, the role of FABP4 in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (ANCA-GN) remains unclear. The current study aimed to investigate the role of FABP4 in patients with ANCA-GN.</p><p><strong>Methods: </strong>Plasma and urine samples from 37 patients with active ANCA-GN and kidney biopsy specimens from another group of 56 patients with ANCA-GN were collected. The plasma and urinary levels of FABP4 were measured by enzyme-linked immunosorbent assay and the kidney FABP4 expression was determined by immunohistochemistry and immunofluorescence staining. Associations between FABP4 levels with clinical and pathologic parameters were analyzed. To further elucidate the role of FABP4 in ANCA-GN, a novel FABP4 inhibitor, BMS309403, was employed in a recognized rat model of experimental autoimmune vasculitis (EAV).</p><p><strong>Results: </strong>Plasma and urinary levels of FABP4 in active ANCA-GN patients were significantly higher than those in normal controls {52.8 ± 23.6 ng/mL vs. 16.9 ± 8.8 ng/mL, <i>p</i> < 0.01; median 126.6 (interquartile range [IQR] 28.4-311.2) ng/g Cr vs. median 0.0 (IQR 0.0-0.0) ng/g Cr, <i>p</i> < 0.01, respectively}. Immunohistochemical analysis revealed higher glomerular and tubular expression of FABP4 in the kidneys of ANCA-GN patients than those in normal controls (0.015 ± 0.012 vs. 0.004 ± 0.003, <i>p</i> < 0.001; 0.053 ± 0.026 vs. 0.011 ± 0.010, <i>p</i> < 0.001, respectively). Moreover, for ANCA-GN patients, urinary FABP4 levels were significantly higher in active ANCA than those in remission (184.3 ± 187.0 ng/g Cr vs. 9.4 ± 23.9 ng/g Cr, <i>p</i> < 0.01). Correlation analysis showed that urinary levels of FABP4 correlated with serum creatinine (<i>r</i> = 0.596, <i>p</i> < 0.0001), urinary albumin/Cr (<i>r</i> = 0.523, <i>p</i> = 0.001), blood neutrophil ratio (<i>r</i> = 0.386, <i>p</i> = 0.018), PT (<i>r</i> = 0.583, <i>p</i> = 0.001), APTT (<i>r</i> = 0.364, <i>p</i> = 0.034), hemoglobin level (<i>r</i> = -0.398, <i>p</i> = 0.015), estimated glomerular filtration rate (<i>r</i> = -0.680, <i>p</i> < 0.0001), crescent proportion (<i>r</i> = 0.661, <i>p</i> = 0.032), and all-cause death of ANCA-GN patients (HR 2.93, 95% CI [1.05-8.19]). Furthermore, FABP4 inhibition by BMS309403 ameliorated renal injury in a rat mole of ANCA-GN.</p><p><strong>Conclusions: </strong>Urinary FABP4 levels might reflect the disease activity and renal involvement of ANCA-associated vasculitis, and FABP4 might act as a promising therapeutic target against ANCA-GN.</p>","PeriodicalId":17830,"journal":{"name":"Kidney Diseases","volume":"11 1","pages":"75-89"},"PeriodicalIF":3.2,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913465/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143649653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Kidney Diseases
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1